Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
New approach to fighting cancer could reduce costs and side effects
UniSA’s Future Industries Institute Ph.D. student Mona Elsemary has developed a microfluidic approach to purify CAR T-cells, the bioengineered immune cells that are the basis of groundbreaking cellular immunotherapy—a transformative cancer therapy that harnesses the power of a patient’s immune system to fight their cancer.
Chemo-free therapy for adult Ph+ ALL
A targeted and immunotherapeutic strategy including dasatinib and the bispecific mAb blinatumomab is able to successfully treat adult patients with Philadelphia-positive acute lymphoblastic leukemia (ALL), inducing 98% of hematological CR and 60% of molecular responses. These results, published on NEJM, were obtained without adding of chemotherapy, an innovative approach associated with high survival rates and few toxic effects.
Tecartus Recommended for EU Approval as CAR T-cell Therapy for Mantle Cell Lymph...
A committee of the European Medicines Agency (EMA) has recommended the conditional approval of Tecartus (brexucabtagene autoleucel) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL).
Immunotherapy Expert Puts Fresh Focus on AEs
In less than 10 years, immune checkpoint inhibitors (ICIs) have dramatically altered the treatment landscape for patients with metastatic melanoma, helping to drive an improvement in 5-year survival rates from historical levels of less than 10% to more than 50% with some regimens.
Enroll in the newly launched 'Processes in CAR-T' course on the EHA Campus
EHA has just launched the third CAR-T course within its EHA immunotherapy program. Reviewed by Professor Ulrich Jäger from Univ. Klinik Innere Medizin I Medizinische Universität Wien, this course addresses processes involved in the manufacture of CAR T-cells from apheresis to treatment, as well as the role of different team members including pharmacists and nurses. It also includes considerations specific to pediatric patients. This module is freely accessible and part of an eight-course program covering all aspects of CAR-T.
EBMT 2020 | NK-CAR immunotherapy: the next steps
Evelyn Ullrich, MD, PhD, Goethe University Frankfurt, Frankfurt, Germany, discusses the next steps with respect to NK-CAR immunotherapy, highlighting a multicenter Phase II study and issues for future studies.
COMy 2020 | The future of immunotherapies for multiple myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the future of multiple myeloma treatment.
NextGen CARs: the race is on
In this issue of Blood, Tong et al present the preclinical and clinical development of an optimized, bivalent tandem CD20/CD19 chimeric antigen receptor (CAR) construct (see figure). Preclinically, they demonstrated dual-antigen specificity, enhanced immune synapse formation, and superior antitumor activity in vitro and in vivo in a murine xenograft model compared with alternative constructs generated from the same 2 single-chain variable fragment (scFv) regions derived from Leu-16 (anti-CD20) and FMC63 (anti-CD19) murine monoclonal antibodie.
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off...
Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial upda...
Cell therapy involves the transplantation of viable cells into a patient in order to trigger a medicinal effect. CAR-T is a popular form of cell therapy, specifically immunotherapy, that can use a patient’s own altered immune cells to fight cancer.